Clinical trials: Cancer of the Fallopian Tube
Peritoneal Carcinomatosis, Ovarian Cancer
Study of Radspherin® in Recurrent Ovarian Cancer Subjects With Peritoneal Carcinomatosis
RAD-18-001 is a First-In-Man, Dose Escalation study conducted at 2 sites. The dose escalation will be performed based on a 3 + 3 design. Increasing dose levels starting at 1 MBq will be followed by 2, 4 and 7 MBq.
- Trial name
- NCT03732768
- Testing
- Radspherin
- Where
- 4 sites in Belgium, Norway and 1 more
- Volunteers
- 21 people
- Sponsor
- Oncoinvent Solutions AS
Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer
A Study to Investigate LYL797 in Adults With Solid Tumors
This study will evaluate the safety and tolerability of LYL797, a ROR1-targeted CAR T-cell therapy, in patients with ROR1+ relapsed or refractory triple negative breast cancer (TNBC), non-small cell lung cancer (NSCLC)…
- Conditions
- Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, Non-small Cell Lung Cancer, Non Small Cell Lung Cancer
- Trial name
- NCT05274451
- Testing
- LYL797
- Where
- 18 sites in United States
- Volunteers
- 57 people
- Sponsor
- Lyell Immunopharma, Inc.
Cervical Cancer, Endometrial Cancer
Liposomal Doxorubicin and Carboplatin in Treating Patients With Gynecologic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Cervical Cancer, Endometrial Cancer, Fallopian Tube Cancer, Ovarian Cancer
- Trial name
- NCT00032162
- Testing
- carboplatin, pegylated liposomal doxorubicin hydrochloride
- Where
- 19 sites in Germany
- Volunteers
- 63 people
- Sponsor
- AGO Study Group
Ovarian Cancer, Fallopian Tube Cancer
Caelyx Plus Carboplatin Versus Paclitaxel Plus Carboplatin in Patients With Epithelial Ovarian Cancer in Late Relapse
This is a study of the efficacy and safety of Caelyx (pegylated liposomal doxorubicin) in combination with carboplatin compared to the standard treatment of paclitaxel and carboplatin in patients with epithelial ovarian cancer in…
- Trial name
- CALYPSO (NCT00189553)
- Testing
- Pegylated liposomal doxorubicin, Carboplatin, Paclitaxel
- Where
- France
- Volunteers
- 976 people
- Sponsor
- ARCAGY/ GINECO GROUP
FIGO Stage IVA Ovarian Cancer, FIGO Stage IVB Ovarian Cancer
Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer
This phase I trial studies the side effects and how well surgery and heated chemotherapy with or without non-heated chemotherapy after surgery works in treating patients with ovarian, fallopian tube, uterine, or peritoneal…
- Conditions
- FIGO Stage IVA Ovarian Cancer, FIGO Stage IVB Ovarian Cancer, Platinum-Resistant Ovarian Carcinoma, Recurrent Fallopian Tube Carcinoma
- Trial name
- NCT01970722
- Testing
- Carboplatin, Cisplatin, Gemcitabine Hydrochloride
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- City of Hope Medical Center
Fallopian Tube Cancer, Ovarian Cancer
Lenalidomide and Doxorubicin Hydrochloride Liposome in Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
RATIONALE: Lenalidomide may stop the growth of cancer by blocking blood flow to the tumor. Drugs used in chemotherapy, such as doxorubicin hydrochloride liposome, work in different ways to stop the growth of tumor cells, either…
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
- Trial name
- NCT00903630
- Testing
- Lenalidomide, liposomal doxorubicin
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Fallopian Tube Cancer, Peritoneal Neoplasms
OVATURE (OVArian TUmor REsponse) A Phase III Study of Weekly Carboplatin With and Without Phenoxodiol in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer
The purpose of this project is to see if weekly carboplatin compared with phenoxodiol in combination with weekly carboplatin, is effective against late stage ovarian cancer and to see what, if any, side-effects of treatment may…
- Conditions
- Fallopian Tube Cancer, Peritoneal Neoplasms, Ovarian Cancer
- Trial name
- OVATURE (NCT00382811)
- Testing
- phenoxodiol, carboplatin
- Where
- 70 sites in United States, Australia and 5 more
- Volunteers
- 142 people
- Sponsor
- MEI Pharma, Inc.
Fallopian Tube Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma
Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This randomized phase II trial studies the side effects of paclitaxel and bevacizumab with or without emactuzumab and how well they work in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has…
- Conditions
- Fallopian Tube Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma
- Trial name
- NCT02923739
- Testing
- Bevacizumab, Emactuzumab, Laboratory Biomarker Analysis
- Where
- 8 sites in United States
- Volunteers
- 9 people
- Sponsor
- M.D. Anderson Cancer Center
Ovarian Cancer, Fallopian Tube Cancer
Japan Phase 2 Study of Niraparib in Participants With Advanced, Relapsed Ovarian Cancer
The purpose of this study is to evaluate the safety and efficacy of niraparib in participants with advanced, relapsed, high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received 3 or 4…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT03759600
- Testing
- Niraparib
- Where
- 33 sites in Japan
- Volunteers
- 20 people
- Sponsor
- Takeda
Ovarian Cancer
Elizabeth Registry for Low Grade Ovarian Cancer
Long-Term Objectives: To establish an ongoing national research registry of epidemiologic, clinical and pathologic data on low grade and low malignant potential (LMP) ovarian cancer patients in UTMDACC's Department of Gynecologic…
- Trial name
- NCT00345709
- Testing
- Questionnaire
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- M.D. Anderson Cancer Center
Relapsed Epithelial Ovarian Cancer, Relapsed Primary Peritoneal Cancer
Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer
This is a dose escalation study in female subjects with relapsed ovarian cancer (including epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer).
- Conditions
- Relapsed Epithelial Ovarian Cancer, Relapsed Primary Peritoneal Cancer, Relapsed Fallopian Tube Cancer
- Trial name
- NCT01940172
- Testing
- Birinapant, Conatumumab
- Where
- 9 sites in United States
- Volunteers
- 27 people
- Sponsor
- TetraLogic Pharmaceuticals
Non-small Cell Lung Cancer, Metastatic Colorectal Cancer
A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Various Cancer
This is a prospective, single-arm, open-label, non-interventional, multicenter, post-marketing surveillance to assess the safety and effectiveness of Zirabev(Bevacizumab biosimilar) in domestic patients with non-small cell lung…
- Conditions
- Non-small Cell Lung Cancer, Metastatic Colorectal Cancer, Metastatic Breast Cancer, Metastatic Kidney Cancer
- Trial name
- NCT04889495
- Testing
- Zirabev
- Sponsor
- Pfizer
High Grade Fallopian Tube Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma
Pembrolizumab and Lenvatinib for the Treatment of Serous Ovarian Cancer Patients
This pilot clinical trial studies the effect of pembrolizumab and lenvatinib in treating patients with high-grade serous ovarian cancers.
- Conditions
- High Grade Fallopian Tube Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma, Peritoneal High Grade Serous Adenocarcinoma, Recurrent High Grade Fallopian Tube Serous Adenocarcinoma
- Trial name
- NCT05114421
- Testing
- Lenvatinib, Pembrolizumab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Castration-Resistant Prostate Cancer, Ovarian Cancer
CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib
This protocol is designed to provide participants currently benefiting from rucaparib treatment in a Clovis-sponsored clinical study with continued access to treatment for as long as they continue to benefit.
- Conditions
- Metastatic Castration-Resistant Prostate Cancer, Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer
- Trial name
- CATCH-R (NCT04676334)
- Testing
- Rucaparib
- Where
- 25 sites in Canada, Israel and 4 more
- Volunteers
- 34 people
- Sponsor
- pharmaand GmbH
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma
Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
This phase II trial studies how well adavosertib with or without olaparib work in treating patients with ovarian, primary peritoneal, or fallopian tube cancer that has come back (recurrent).
- Conditions
- Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Trial name
- NCT03579316
- Testing
- Adavosertib, Olaparib, Ceralasertib
- Where
- 2 sites in United States
- Volunteers
- 96 people
- Sponsor
- M.D. Anderson Cancer Center
Ovarian Neoplasms, Fallopian Tube Neoplasms
Vandetanib to Treat Women With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Background: Vandetanib is a drug that attacks a group of proteins on the surface of many cells, especially blood vessel cells and tumor cells. Tumors require the development of new blood vessels in order to grow and spread.
- Conditions
- Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms
- Trial name
- NCT00445549
- Testing
- Vandetanib
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian Cancer, Ovarian Neoplasms
Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer
Pegylated liposomal doxorubicin (PLD), a type of chemotherapy, is a standard treatment option for patients with platinum-resistant ovarian cancer.
- Conditions
- Ovarian Cancer, Ovarian Neoplasms, Ovarian Carcinoma, Fallopian Tube Cancer
- Trial name
- NCT05261490
- Testing
- maplirpacept (PF-07901801), Pegylated Liposomal Doxorubicin (PLD)
- Where
- 18 sites in United States
- Volunteers
- 10 people
- Sponsor
- Pfizer
Ovarian Cancer, Primary Peritoneal Carcinoma
PDL-1 Inhibition and Focal Sensitizing Radiotherapy in Recurrent Ovarian/Primary Peritoneal/Fallopian Tube Cancers.
It is postulated that focal sensitizing radiotherapy may potentiate the effectiveness of durvalumab. The purpose of this study is to test the safety and tolerability of 2 different dose levels of focal sensitizing radiation…
- Conditions
- Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
- Trial name
- NCT03283943
- Testing
- Focal radiotherapy, Durvalumab
- Where
- Canada
- Volunteers
- 22 people
- Sponsor
- British Columbia Cancer Agency
Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma
Paclitaxel + Carboplatin With AVB-S6-500 in Women With Stage III or IV Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Receiving Neoadjuvant Chemotherapy
The receptor tyrosine kinase AXL is a pathway that plays a crucial role in metastasis and chemoresistance. Overexpression of AXL has been associated with metastasis, recurrence, and chemoresistance in various cancer including…
- Conditions
- Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
- Trial name
- NCT03607955
- Testing
- AVB-S6-500, Paclitaxel, Carboplatin
- Sponsor
- Washington University School of Medicine
Fallopian Tube Cancer, Ovarian Cancer
Autologous T Cells With or Without Cyclophosphamide and Fludarabine in Treating Patients With Recurrent or Persistent Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer (Fludarabine Treatment Closed as of 12/01/2009)
RATIONALE: Giving colony-stimulating factors, such as G-CSF, helps stem cells move from the bone marrow to the blood so they can be collected.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00562640
- Testing
- filgrastim, therapeutic autologous lymphocytes, cyclophosphamide
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Memorial Sloan Kettering Cancer Center